News|Articles|January 9, 2024
Prioritizing R&D Initiatives to Support Cell Line Development (January 2024)
Author(s)AGC Biologics
Robust, scalable manufacturing of novel therapeutics requires partnering with a CDMO equipped to adapt to changes in the market and knowledgeable on the latest technologies used to support cell line development.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
RNAnalytics CPHI Interview, Part Two: Nanoparticle Case Studies and Response to US mRNA Pullback
2
Why Data Quality, Not Regulation, Is the True Barrier to AI in Biologics
3
How Is AI Transforming Biomanufacturing and Biopharma Workforce Training?
4
Strategic Shifts for Speed, Resilience, and Long-Term Sustainability in Biomanufacturing
5
